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Objectives The aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor,
des-fluoro-sitagliptin (DFS).
Background The new class of anti–type 2 diabetes drugs, dipeptidyl peptidase-4 inhibitors, improves glucose metabolism by
increasing levels of active glucagon-like peptide (GLP)-1.
Methods Endothelial function was examined by acetylcholine-induced endothelium-dependent vasorelaxation using aortic rings
and atherosclerotic lesion development in the entire aorta in apolipoprotein E–deficient mice fed a high-fat diet with
or without DFS, and the antiatherogenic effects of DFS were investigated in cultured human macrophages and endo-
thelial cells. Plasma levels of active GLP-1 were measured in patients with or without coronary artery disease.
Results DFS significantly improved endothelial dysfunction (89.9  3.9% vs. 79.2  4.3% relaxation at 104 mol/l
acetylcholine, p  0.05) associated with increased endothelial nitric oxide synthase phosphorylation and re-
duced atherosclerotic lesion area (17.7% [15.6% to 25.8%] vs. 24.6% [19.3% to 34.6%], p  0.01) compared
with vehicle treatment. In cultured human macrophages, DFS significantly increased GLP-1-induced cytosolic
levels of cyclic adenosine monophosphate compared with GLP-1 alone, resulted in inhibiting phosphorylation of
c-jun N-terminal kinase and extracellular signal-regulated kinase 1/2 and nuclear factor-kappa B p65 nuclear
translocation through the cyclic adenosine monophosphate/protein kinase A pathway, and suppressed proin-
flammatory cytokines (i.e., interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha) and monocyte che-
moattractant protein-1 production in response to lipopolysaccharide. DFS-enhanced GLP-1 activity sustained en-
dothelial nitric oxide synthase phosphorylation and decreased endothelial senescence and apoptosis compared
with GLP-1 alone. In the human study, fasting levels of active GLP-1 were significantly lower in patients with cor-
onary artery disease than those without (3.10 pmol/l [2.40 to 3.62 pmol/l] vs. 4.00 pmol/l [3.10 to 5.90 pmol/l],
p  0.001).
Conclusions A DPP-4 inhibitor, DFS, exhibited antiatherogenic effects through augmenting GLP-1 activity in macrophages and
endothelium. (J Am Coll Cardiol 2012;59:265–76) © 2012 by the American College of Cardiology Foundation
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Antiatherogenic Actions of DPP-4 Inhibitor January 17, 2012:265–76Diabetes mellitus (DM) increases
the risk for atherosclerosis and car-
diovascular disease, but whether
antidiabetic medications reduce
cardiac events remains controver-
sial (1). Moreover, intensive glu-
cose control does not seem to be
beneficial in preventing major car-
diovascular events compared with
standard therapy (2). The new
class of anti–type 2 DM drugs,
dipeptidyl peptidase (DPP)-4 in-
hibitors and glucagon-like peptide
(GLP)-1 analogues, improve glu-
cose metabolism through the acti-
vation of GLP-1 receptor signal-
ing, which induces insulin secretion
and suppresses glucagon secre-
tion in the pancreas (3). Several
studies have shown the beneficial
effects of GLP-1 on the cardio-
vascular system (4,5). In contrast,
there is a lack of evidence for the
beneficial effects of DPP-4 inhib-
itors on the cardiovascular system.
Atherosclerosis is an inflam-
matory disease of the arterial
wall, and endothelial dysfunction
has been shown to contribute to
atherogenesis (6,7). Approaches
designed to reduce the inflammatory activity and improve
endothelial function may have additional therapeutic value
in the prevention and treatment of atherosclerotic diseases,
including coronary artery disease (CAD) (8).
See page 277
In the present study, we tested the hypothesis that enhance-
ment of GLP-1 action with a DPP-4 inhibitor has anti-
inflammatory effects on macrophages and can result in
amelioration of endothelial dysfunction, leading to a slow-
down in the progression of atherosclerosis. For this purpose,
we investigated the antiatherogenic effects of a DPP-4
inhibitor in apolipoprotein E (apoE)–deficient mice fed a
high-fat diet (HFD) with or without a DPP-4 inhibitor. In
a human study, we also measured fasting plasma levels of
active GLP-1 in patients with or without CAD.
(grant C22590786 to Dr. Sugiyama) from the Ministry of Education, Science, and
Culture of Japan and grant support from Merck & Company, Inc. All authors have
reported that they have no relationships relevant to the contents of this paper to
disclose.
Abbreviations
and Acronyms
apoE  apolipoprotein E
CAD  coronary artery
disease
cAMP  cyclic adenosine
monophosphate
DFS  des-fluoro-sitagliptin
DM  diabetes mellitus
DPP  dipeptidyl peptidase
eNOS  endothelial nitric
oxide synthase
ERK  extracellular signal-
regulated kinase
GLP  glucagon-like
peptide
HCAEC  human coronary
artery endothelial cell
HFD  high-fat diet
IL  interleukin
JNK  c-jun N-terminal
kinase
LPS  lipopolysaccharide
mRNA  messenger
ribonucleic acid
NF-B  nuclear factor–
kappa B
PKA  protein kinase AManuscript received May 27, 2011; revised manuscript received July 5, 2011,
accepted July 19, 2011.Methods
The DPP-4 inhibitor, des-fluoro-sitagliptin (DFS) was sup-
plied by Merck & Company, Inc. (Rahway, New Jersey). In
animal experiments, 4-weeks-old apoE-deficient mice
(C57BL/6.KOR-Apoeshl) were purchased from SLC, Inc.
(Shizuoka, Japan). The mice were fed a standard diet (Re-
search Diets, New Brunswick, New Jersey) for 2 weeks,
followed by an HFD (35% kcal from fat; Research Diets). For
mice in the DFS group, DFS was mixed with baked HFD at
a final concentration of 0.3% (corresponding to 200 mg/kg/day).
After treatment for 16 weeks, whole aortas were collected
and stained with Oil Red O. The extent of atherosclerosis
was expressed as the percent of the lesion area extending
from the ascending aorta to the abdominal bifurcation.
In cell culture studies, the human monocytic cell line
THP-1 was purchased from the American Type Culture
Collection (Manassas, Virginia). These cells were cultured
additionally in 10 ng/ml granulocyte macrophage colony-
stimulating factor, 10 ng/ml macrophage colony-stimulating
factor, and 16 nmol/l phorbol 12-myristate 13-acetate for dif-
ferentiation into macrophages. These cells were then used as
“THP-1 cell-derived macrophages” after the 4-days culture.
Human coronary artery endothelial cells (HCAECs) (Lonza
Walkersville, Inc., Walkersville, Maryland) and human aortic
endothelial cells (Lonza Walkersville, Inc.) were cultured in
EGM-2MV medium (Lonza Walkersville, Inc.) under standard
ulture condition. Cells were pre-treated with or without DFS
2 mol/l) for 1 h, followed by treatment with or without
GLP-1 (10 pmol/l).
In human studies, plasma concentrations of active GLP-1
were measured in patients admitted to Kumamoto Univer-
sity Hospital (Kumamoto, Japan). A total of 200 patients
with or without CAD were recruited.
Statistical analysis. Group data of normally distributed con-
tinuous variables are expressed as mean  SD or mean 
SEM as indicated. Medians and interquartile ranges are
reported for parameters with skewed distributions. Differ-
ences between 2 variables were tested using unpaired Stu-
dent’s t tests or Mann-Whitney U tests. Data of multiple
groups were compared using 1-way analysis of variance
followed by post hoc Tukey-Kramer tests. A p value  0.05
was considered statistically significant. All analyses were
performed using SPSS version 17.0J for Windows (SPSS
Japan Inc., Tokyo, Japan).
An expanded Methods section is available in the Online
Appendix.
Results
Animal experiments. DFS REDUCED ATHEROSCLEROTIC
LESION FORMATION. ApoE-deficient mice were treated for
16 weeks with DFS (Fig. 1A). As shown in Online
Appendix Table 1, DFS had no significant effects on mean
body weight, systolic blood pressure, heart rate, lipid profile,
fasting glucose, and insulin. The relative surface area of the
atherosclerotic lesion was significantly smaller in the DFS
267JACC Vol. 59, No. 3, 2012 Matsubara et al.
January 17, 2012:265–76 Antiatherogenic Actions of DPP-4 InhibitorFigure 1 DFS Reduces Atherosclerotic Lesion Formation in ApoE-Deficient Mice
(A) The protocol used for analysis of the antiatherogenic effects of des-fluoro-sitagliptin (DFS). (B) The relative surface area of the atherosclerotic lesion in vehicle-
treated and DFS-treated apolipoprotein E (apoE)–deficient mice (n  18 each; p values by Mann-Whitney U tests). (C) Fasting and postprandial plasma levels of active
glucagon-like peptide (GLP)-1 in DFS-treated and vehicle-treated apoE-deficient mice (n  18 each; p values by Student’s t tests). (D) Plasma glucose levels during intra-
peritoneal glucose tolerance test (IPGTT). (E) Plasma insulin levels during IPGTT. (F) Plasma glucose levels during oral glucose tolerance test (OGTT). (G) Plasma insulin
levels during OGTT. Values are mean  SD.
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Antiatherogenic Actions of DPP-4 Inhibitor January 17, 2012:265–76group compared with the vehicle group (17.7% [15.6% to
25.8%] vs. 24.6% [19.3% to 34.6%], n  18 each, p  0.01)
(Fig. 1B). The fasting and post-prandial plasma levels of active
GLP-1 were higher in the DFS group than in the vehicle
groups (fasting: 17.8  6.2 pg/ml vs. 10.8  2.9 pg/ml;
post-prandial: 63.5  30.8 pg/ml vs. 38.1  13.3 pg/ml;
n 18 each; p 0.01) (Fig. 1C). Furthermore, the univariate
logistic regression analysis revealed that only fasting levels of
active GLP-1 were significantly correlated with the high
percent atherosclerotic area group (odds ratio: 0.80; 95%
confidence interval: 0.67 to 0.97; p  0.05), but not the other
factors. Intraperitoneal glucose tolerance testing showed no
differences in plasma glucose and insulin concentrations be-
tween the DFS and vehicle groups or even between the
pre-treatment and standard diet treatment groups (Figs. 1D
and 1E). On oral glucose tolerance testing, the blood glucose
levels after glucose load were significantly decreased and the
plasma insulin levels after glucose load were significantly
increased in the DFS group than the other groups. However,
the glucose and insulin levels at 0 and 120 min after glucose
load were not different among all groups (Figs. 1F and 1G).
Histological analysis of Oil Red O–stained sections of the aortic
sinus indicated a significant reduction in lipid-rich atherosclerotic
lesion area in the DFS group compared with the vehicle group
(42.6 3.5% vs. 48.9 6.7%, n 18 each, p 0.01) (Fig. 2A).
istological analysis of macrophage-stained aortic sinus also
ndicated that DFS treatment significantly reduced the area of
acrophages in plaques compared with vehicle treatment (15.6
.9% vs. 20.8  6.7%, n  18 each, p  0.05) (Fig. 2B).
urthermore, DFS treatment significantly decreased T lympho-
yte infiltration within the lesions in the aortic sinus compared
ith vehicle treatment (10.5 2.3 cells vs. 13.2 3.7 cells, n
8 each, p  0.05) (Fig. 2C).
We confirmed that aortic expression of DPP-4 and GLP-1
eceptor messenger ribonucleic acid (mRNA) was not signifi-
antly different between the DFS and vehicle groups (DPP-4
 0.83; GLP-1 receptor p  0.95) (Fig. 2D). DFS
reatment significantly reduced the aortic mRNA expression
evels of interleukin (IL)-6, IL-1-beta, tumor necrosis factor-
lpha, monocyte chemoattractant protein-1, intercellular
dhesion molecule-1, and vascular cell adhesion molecule-1
Fig. 2D), but not that of IL-10 (p  0.72) (Fig. 2D).
DFS IMPROVED ENDOTHELIAL FUNCTION. ApoE-deficient
ice were treated with DFS, vehicle, or standard diet for 7 weeks
Fig. 3A, Online Table 2). DFS treatment significantly increased
asting plasma levels of active GLP-1 compared with the vehicle
nd control groups (DFS 16.7  3.6 pg/ml, vehicle 9.9  2.8
g/ml, control 10.6 2.7 pg/ml, p 0.001) (Fig. 3B). Ingestion
f the HFD worsened the vascular endothelium–dependent
elaxation in response to acetylcholine. However, DFS signifi-
antly improved the vascular endothelium–dependent relaxation
n response to acetylcholine compared with the vehicle group
89.9  3.9% vs. 79.2  4.3% relaxation at 104 mol/l acetyl-
holine, n 7 each, p 0.05) (Fig. 3C). In contrast, the vascular
ndothelium–independent relaxation in response to sodium nitro-russide did not differ among the 3 groups (data not shown). We
ound that DFS treatment significantly increased endothelial
itric oxide synthase (eNOS) phosphorylation compared with the
ehicle (1.46  0.16-fold, n  7 each, p  0.05) (Fig. 3D),
lthough the total eNOS protein was not different between the 2
roups.
ell culture studies. ENHANCED GLP-1 ACTIVITY BY DFS
NCREASED CYCLIC ADENOSINE MONOPHOSPHATE (CAMP)
EVELS, LEADING TO REDUCED EXPRESSION OF LIPOPOLY-
ACCHARIDE (LPS)–INDUCED INFLAMMATORY CYTOKINES
ND THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN
ULTURED HUMAN MACROPHAGES. Reverse transcriptase
polymerase chain reaction and Western blot analyses
showed the expression of DPP-4 and GLP-1 receptor on
human monocytes, THP-1 cell–derived macrophages (days
1 and 4), HCAECs, and human aortic endothelial cells
(Figs. 4A and 4B).
As shown in Figure 4C, LPS-induced inflammation (eval-
uated by IL-6 production) was significantly attenuated by 20 to
100 pmol/l active GLP-1, but not by the physiological levels of
active GLP-1 (10 pmol/l) alone. Co-incubation of macro-
phages with DFS and physiological levels of GLP-1 signifi-
cantly reduced LPS-induced production of inflammatory cy-
tokines and monocyte chemoattractant protein-1 in a dose-
dependent manner of DFS (Figs. 4D to 4G). In contrast, DFS
and GLP-1 had no effect on LPS-induced production of
IL-10 (p  0.88) (Fig. 4H).
The IL-4-induced macrophage production of IL-10 was
significantly increased compared with control. However,
DFS and GLP-1 had no effect on the IL-4–induced
production of IL-10 compared with DFS or GLP-1 alone
(Online Fig. 1A). The mRNA levels of CD204 and
transforming growth factor–beta were also significantly
induced by IL-4 in macrophages, but they were not signif-
icantly different between DFS and GLP-1 and DFS or
GLP-1 alone (Online Fig. 1B).
Pre-treatment with DFS significantly enhanced the cytosolic
levels of cAMP induced by GLP-1 (after 60 min,20.1 6.8%,
p  0.05; area under the curve 24.0  1.7%, p  0.001)
(Fig. 5A), resulting in a significant inhibition of LPS-induced
phosphorylation of extracellular signal-regulated kinase (ERK)
1/2 and c-jun N-terminal kinase (JNK) compared with GLP-1
alone (ERK 1/2: after 5 min,49.4 16.5%, p 0.01, after 15
min,42.6 11.5%, p 0.01; JNK: after 5 min,65.8 6.7%,
p 0.001, after 15 min,60.4 9.3%, p 0.01) (Figs. 5B and
5C). DFS and GLP-1 treatment significantly inhibited LPS-
induced phosphorylation of inhibitor of kappa B kinase–beta and
nuclear factor–kappa B (NF-B) p65 nuclear translocation com-
ared with GLP-1 alone (inhibitor of kappa B kinase–beta56.7
3.5%, p 0.001; NF-B70.8 4.8%, p 0.001) (Figs. 5F
nd 5H). The addition of MDL-12,330A, a specific adenylyl
yclase inhibitor, and H89, a specific protein kinase A (PKA)
nhibitor, significantly attenuated the inhibitory effects of DFS
nd GLP-1 on LPS-induced phosphorylation of ERK 1/2, JNK,
nd inhibitor of kappa B kinase–beta, and NF-B activation(Figs. 5D, 5E, 5G, and 5H). Furthermore, the production of
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January 17, 2012:265–76 Antiatherogenic Actions of DPP-4 InhibitorFigure 2 DFS Reduces Atherosclerotic Lesion Formation, Amount of Macrophages Within Plaque,
and Proinflammatory Cytokines in ApoE-Deficient Mice
(A to C) Histological analyses of (A) atherosclerotic lesion area (Oil Red O stain), (B) amount of macrophages in plaque (anti-CD68 stain), and (C) T lymphocyte infiltra-
tion within plaque lesions (anti-CD90 stain) in aortic sinuses of vehicle-treated and des-fluoro-sitagliptin (DFS)–treated apolipoprotein E (apoE)–deficient mice (n  18
each, p values by Student’s t tests). Scale bars  500 m in A and B and 200 m in C. Arrows in C point to infiltrating T lymphocytes. (D) Relative messenger ribonu-
cleic acid (mRNA) expression levels of dipeptidyl peptidase (DPP)-4, glucagon-like peptide (GLP)-1 receptor, interleukin (IL)-10, IL-6, IL-1-beta, tumor necrosis factor-alpha
(TNF-), monocyte chemoattractant protein (MCP)-1, vascular cell adhesion molecule (VCAM)-1, and intercellular adhesion molecule (ICAM)-1 measured by quantitative
real-time reverse transcriptase polymerase chain reaction in the aortas (n  6 each) and expressed relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression. Values represent fold of the mean value measured in controls. p  0.05 versus vehicle. Values are mean  SD.
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Antiatherogenic Actions of DPP-4 Inhibitor January 17, 2012:265–76reactive oxygen species from macrophages treated with DFS and
GLP-1 as significantly decreased compared with those treated
with DFS or GLP-1 alone (Online Fig. 2).
DFS-INDUCED ENHANCEMENT OF GLP-1 ACTIVITY IN-
CREASED ENOS PHOSPHORYLATION AND INHIBITED PREMA-
TURE SENESCENCE AND OXIDATIVE STRESS–INDUCED APO-
PTOSIS OF HCAECS. Both GLP-1 alone and GLP-1
combined with DFS (at 2 and 5 min after the addition of
GLP-1) significantly increased eNOS phosphorylation in
Figure 3 DFS Improves Endothelial Function in ApoE-Deficient
(A) Schematic diagram of the study protocol. (B) Fasting plasma levels of active G
and standard diet group (n  8). (C) Vascular endothelium–dependent relaxation
of mice in the vehicle and DFS groups (n  7 each). Values are mean  SD. AbbrHCAECs. However, GLP-1 combined with DFS succeeded in
significant continuation of eNOS phosphorylation at 10 min
(1.47  0.04-fold, p  0.001) (Fig. 6A). Furthermore, the
ddition of MDL-12,330A and H89 significantly suppressed the
nhancing effects of DFS on GLP-1–induced eNOS phosphor-
lation (Fig. 6B).
Cotreatment with DFS and GLP-1 significantly de-
reased the number of senescence-associated beta-
alactosidase-positive cells compared with GLP-1 alone
n the high-fat diet (HFD) with DFS group (n  7), HFD with vehicle group (n  7),
tylcholine (ACh). (D) Western blot analysis using protein samples from the aortas
ns as in Figure 1.Mice
LP-1 i
to ace
eviatio
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January 17, 2012:265–76 Antiatherogenic Actions of DPP-4 InhibitorFigure 4 Anti-Inflammatory Effects of DFS in Cultured Human Macrophages
Reverse transcriptase polymerase chain reaction (RT-PCR) (A) and Western blot (B) analyses indicated that human monocytes, THP-1 cell–derived macrophages, human
coronary artery endothelial cells, and human aortic endothelial cells expressed dipeptidyl peptidase–4 (DPP-4) and GLP-1 receptor. (C) Effect of treatment of THP-1–
derived macrophages with the indicated concentrations of GLP-1 (10 to 100 pmol/l), followed by stimulation with 10 ng/ml lipopolysaccharide (LPS) on the production of
IL-6 (n  5 or 6). (D to H) Effects of co-incubation of macrophages with GLP-1 (10 pmol/l) and DFS on LPS-induced production of (D) IL-6, (E) IL-1-beta, (F) TNF-,
(G) MCP-1, and (H) IL-10. Values are means of percent reduction compared with GLP-1 alone. Bars are mean  SEM values on 5 or 6 experiments. Abbreviations as in
Figures 1 and 2.
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otreatment with GLP-1 and DFS significantly de-
reased the percent of apoptotic HCAECs induced by
00 mol/l H2O2 (annexin-V
/propidium iodide)
ompared with GLP-1 alone (11.0  0.6% vs. 23.6 
Figure 5 Effect of DFS on Cytosolic cAMP Levels and ERK 1/2
and NF-B Activation in Cultured Human Macrophage
(A) Effects of pre-treatment of THP-1–derived macrophages with 2 mol/l DFS followe
(cAMP). AUC  area under the curve. (B,C) Effects of pre-treatment of macrophages w
intracellular levels of extracellular signal-regulated kinase (ERK) 1/2 (B) and c-jun N-te
at 15 min after LPS stimulation. (D,E,G) Effects of treatment of macrophages with 5 
(D) and JNK (E) activation at 5 min and IKK (G) at 15 min after LPS stimulation (n 
lower band 42 kDa); (bottom) immunoblot with anti–ERK 1/2 (upper band 44 kDa, lo
antiphosphorylated JNK (upper band 54 kDa, lower band 46 kDa); (bottom) immunob
ples). Values are means of the percent reduction compared with GLP-1 alone. (F,G) (T
[IKK] 85 kDa); (bottom) anti-IKK (band 87 kDa) as control (representative samples
12,330A, 5 mol/l H89, DFS (2 mol/l), and GLP-1 (10 pmol/l) followed by 10 ng/m
(n  6 each). Immunoblot with anti-NF-B p65 nuclear translocation (band 65 kDa). B.4%, p  0.001) (Fig. 7A). Pre-treatment with
-NAME, the eNOS inhibitor, significantly attenuated
he inhibitory effects of DFS and GLP-1 on endothelial
enescence and apoptosis (Figs. 6D and 7B). The intra-
ellular defensive factors against oxidative stress (Cu-Zn-
JNK Phosphorylation
0 pmol/l GLP-1 (n  6 each) on cytosolic levels of cyclic adenosine monophosphate
mol/l DFS followed by 10 pmol/l GLP-1 and 10 ng/ml lipopolysaccharide (LPS) on
kinase (JNK) (C) at 5 and 15 min and inhibitor of kappa B kinase–beta (IKK) (F)
MDL-12,330A, 5 mol/l H89, DFS (2 mol/l) and GLP-1 (10 pmol/l) on ERK 1/2
ch). (B,D) (Top) Immunoblot with antiphosphorylated ERK 1/2 (upper band 44 kDa,
nd 42 kDa) as control (representative samples). (C,E) (Top) Immunoblot with
anti-JNK (upper band 54 kDa, lower band 46 kDa) as control (representative sam-
munoblot with antiphosphorylated IKK/ (upper band [IKK] 87 kDa, lower band
ffects of treatment of nuclear extracts from macrophages with 5 mol/l MDL-
on activation nuclear factor–kappa B (NF-B) at 20 min after LPS stimulation
resent the mean  SEM values. Abbreviations as in Figure 1.and
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oredoxin) were significantly increased in HCAECs
treated with DFS and GLP-1 compared with those
treated with DFS or GLP-1 alone (Fig. 7C).
Figure 6 Effects of DFS on Endothelial Cell Function
(A) Human coronary artery endothelial cells (HCAECs) were pre-treated with DFS (2
phorylation of endothelial nitric oxide synthase (eNOS) at 2, 5, and 10 min after G
pre-treated with 5 mol/l MDL-12,330A, 5 mol/l H89, or vehicle for 30 min befo
tion was quantified by Western blots (n  6 each). (Top) Immunoblot with anti-pho
kDa) as control (representative samples). (C) HCAECs were treated with or without
mmol/l L-NAME for 30 min before treatment with GLP-1.The medium was changed
At the 10th (C) or 5th (D) day, HCAECs were fixed, and the proportion of senesce
means of the percent reduction compared with GLP-1 alone. (D) Values are mean
viations as in Figure 1.Furthermore, GLP-1 combined with DFS significantly re-
duced the mRNA levels of basal expression and those induced by
IL-1-beta of intercellular adhesion molecule–1 (basal 11.0 
.5%, p 0.05; IL-1-beta20.0 7.5%; p 0.05) and vascular
l/l) or vehicle for 1 h, then treated with GLP-1 (10 pmol/l) or vehicle. The phos-
dministration was quantified by Western blots (n  6 each). (B) HCAECs were
addition of GLP-1. The phosphorylation of eNOS at 2 min after GLP-1 administra-
ylated eNOS (band 140 kDa); (bottom) immunoblot with anti-eNOS (band 140
mol/l) and GLP-1 (10 pmol/l). (D) HCAECs were pre-treated with or without 1
DFS, GLP-1, and L-NAME were added every day at the indicated concentrations.
sociated beta-galactosidase staining was determined (n  6 each). Values are
e percent reduction compared with GLP-1 alone. Values are mean  SEM. Abbre-mo
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Antiatherogenic Actions of DPP-4 Inhibitor January 17, 2012:265–76cell adhesion molecule–1 (basal 13.1  5.7%, p  0.05;
L-1-beta 28.0  10.3%, p  0.05) compared with GLP-1
lone (Online Figs. 3A and 3B).
Figure 7 Effects of DFS on Apoptosis
(A) Human coronary artery endothelial cells (HCAECs) pre-treated with DFS (2 mo
by stimulation with 100 mol/l H2O2 for 30 min (n  6 each). (B) HCAECs were p
Fluorescence-activated cell sorting derived dot plot of HCAECs stained with annexi
PI staining (lower right quadrants). Values are means of the percent reduction co
nificantly increased in HCAECs treated with DFS (2 mol/l) and GLP-1 (10 pmol/l)
dismutase (SOD), glutathione peroxidase (GPX), and thioredoxin (TXN) measured b
HCAECs treated with or without DFS (2 mol/l) for 1 h, followed by treatment with
3-phosphate dehydrogenase (GAPDH) expression (n  6 each). Values are mean DFS MODULATED THE PROINFLAMMATORY RESPONSE IN
PERITONEAL MACROPHAGES. In apoE-deficient mice, the
FD significantly induced the mRNA expression of
vehicle for 1 h, then treated with GLP-1 (10 pmol/l) or vehicle for 1 h, followed
ted with or without 1 mmol/l L-NAME for 30 min before treatment with GLP-1.
C and propidium iodide (PI). Apoptotic cells were identified by annexin-V-FITC/
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January 17, 2012:265–76 Antiatherogenic Actions of DPP-4 Inhibitorproinflammatory factors in peritoneal macrophages after
4 weeks (p  0.05). DFS treatment significantly reduced
the mRNA expression levels of IL-6, IL-1-beta, and
monocyte chemoattractant protein-1 (p  0.05 for each)
and tended to reduce the mRNA expression levels of
tumor necrosis factor-alpha (p  0.31). DFS did not
xhibit significant effects on the mRNA expression levels
f IL-10, IL-4, and transforming growth factor– beta
Online Fig. 4).
uman studies. LOW FASTING PLASMA LEVELS OF ACTIVE
GLP-1 IN PATIENTS WITH CAD. Online Appendix Table 3 lists
the clinical characteristics of patients with or without CAD.
The proportion of patients with CAD with fasting levels of
active GLP-1 below the detection limit (2.0 pmol/l; n  19)
was significantly higher than those without CAD (n 8) (p
0.05). Furthermore, the fasting plasma levels of active GLP-1
in patients with CAD (n  81) were significantly lower than
n those without CAD (n  92), excluding patients with
ndetectable levels of active GLP-1 (3.10 pmol/l [2.40 to 3.62
mol/l] vs. 4.00 pmol/l [3.10 to 5.90 pmol/l], p  0.001)
Online Fig. 5A). Among patients without DM, the fasting
lasma levels of active GLP-1 in patients with CAD (n 58)
ere also significantly lower than in those without CAD (n
0), excluding patients with undetectable levels of active
LP-1 (3.20 pmol/l [2.60 to 3.70 pmol/l] vs. 3.90 pmol/l
3.00 to 5.20 pmol/l], p  0.001) (Online Fig. 5B). The
ultivariate logistic regression analysis revealed that the lower
ctive GLP-1 independently correlated with the presence of
AD after adjustment for significant factors by univariate logistic
egression (lower group; odds ratio: 5.87; 95% confidence interval:
.42 to 14.19; p 0.001; Hosmer-Lemeshow test p 0.59) and
n the forced-entry models (lower group; odds ratio: 5.62; 95%
onfidence interval: 2.83 to 11.14; p  0.001; Hosmer-
emeshow test p  0.77) (Online Table 4).
iscussion
he present study demonstrated that the DPP-4 inhibitor
FS reduced atherosclerosis lesion formation and improved
ndothelial dysfunction in apoE-deficient mice independent
f fasting glucose and lipid profile. Furthermore, when the
hysiological concentrations of GLP-1 and DFS were used in
he in vitro experiments, DFS significantly increased the
ytosolic levels of cAMP induced by GLP-1 and consequently
educed the expression of proinflammatory mediators in hu-
an cultured macrophages, as well as increasing phosphoryla-
ion of eNOS and reducing senescence and apoptosis in
ultured HCAECs, compared with GLP-1 alone.
Inflammatory responses mediated by inflammatory cytokines
re considered important in all stages of atherosclerosis (7). The
resent study showed that DFS reduced the mRNA expression
evels of proinflammatory mediators in the aortas of apoE-
eficient mice. Indeed, the present animal studies showed that
FS decreased the percent area of macrophages and T lympho-
ytes in the plaques and reduced expression of proinflammatory
actors in peritoneal macrophages. Furthermore, coapplication ofFS and GLP-1, but not DFS or GLP-1 alone, significantly
educed the production of reactive oxygen species and proinflam-
atory mediators in human cultured macrophages and attenuated
he expression of intercellular adhesion molecule-1 and vascular
ell adhesion molecule-1 in HCAECs. According to the results
hown in Figures 4E and 6D and Online Figures 1 and 3D,
reatment with DFS and GLP-1 could exhibit antiatherogenic
nd anti-inflammatory effects through a possible direct link be-
ween the effects of DFS and GLP-1 on macrophages and those
n endothelial cells.
Experimental evidence suggests that the control of dys-
egulated mitogen-activated protein kinase cascade and
F-B activation could be a potential target in the treat-
ment of atherosclerosis (9,10). Arakawa et al. (4) showed
that the GLP-1 receptor agonist exendin-4 reduced athero-
sclerotic lesion in mice and that this effect may contribute to
the inhibition of NF-B p65 nuclear translocation in
macrophages by increased cAMP levels elicited by GLP-1
receptor activation. The present study further showed that
DFS significantly increased the level of GLP-1-induced
cytosolic cAMP and consequently inhibited the activation
of intracellular inflammatory signaling through the cAMP/
PKA pathway in human cultured macrophages. These
findings suggest that inhibition of the inflammatory activity
of macrophages by enhancing GLP-1 receptor activation
using DFS could attenuate inflammation and modulate the
atherogenic process via the cAMP/PKA pathway.
Nitric oxide, produced by eNOS, plays important roles in
vascular biology, including regulation and coordination of endo-
thelial cell function, proliferation, senescence, and apoptosis (11),
and exhibits atheroprotective effects (12). PKA activates eNOS in
endothelial cells (13). The present study showed that DFS
improved HFD-induced endothelial dysfunction by increasing
the phosphorylation of eNOS in apoE-deficient mice. Further-
more, the in vitro experiments showed that DFS increased or
augmented GLP-1 activity and thereby enhanced the phosphor-
ylation of eNOS through the cAMP/PKA pathway and de-
creased the endothelial inflammation, senescence, and apoptosis
of HCAECs. Pre-treatment with L-NAME significantly atten-
uated the inhibitory effects of DFS and GLP-1 on endothelial
inflammation, senescence, and apoptosis. These results suggest
that DPP-4 inhibitors might, at least in part, inhibit atheroscle-
rosis by protecting endothelial functions and preserving endothe-
lial integrity. However, it is not clear whether eNOS phosphory-
lation could be activated by GLP-1 through the other signaling
pathways. Further experiments would be needed to determine the
details of intracellular signaling mechanisms of the enhanced
eNOS phosphorylation by DFS and GLP-1.
Intraperitoneal glucose tolerance testing showed no differ-
ences in plasma glucose and insulin concentrations among all
groups in the present study. The results indicate that this
mouse model was not diabetic. On oral glucose tolerance
testing, differences among plasma glucose levels after glucose
load were small but significantly decreased in the DFS group
compared with the vehicle group, confirming the enhancement
of incretin effects by DFS. The present study also showed that
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Antiatherogenic Actions of DPP-4 Inhibitor January 17, 2012:265–76low levels of fasting active GLP-1 were significantly correlated
with the high percent atherosclerotic area in mice model.
Furthermore, the human studies demonstrated that the fasting
plasma levels of active GLP-1 were significantly lower in
patients with CAD than those without CAD (Online Figs. 5A
and 5B). According to these results, the endogenous GLP-1
activity augmented by DPP-4 inhibitors could exhibit anti-
atherogenic effects.
CD26 is a cell surface protein with DPP-4 enzymatic activity,
as well as a multifunctional protein involved in T lymphocytes
activation and correlated with the production of T helper 1–type
responses (14). There is a concept emerging from numerous lines
of evidence that macrophages can develop into different subsets:
classic macrophages, activated by T helper 1–type responses, or
alternative macrophages, activated by T helper 2–type responses
(15). In a previous study, DPP-4 inhibition in vivo by genetic and
pharmacological blockade did not affect T lymphocyte–
dependent immune responses (16). Treatment with sitagliptin, a
DPP-4 inhibitor, has been reported to have no clinical effect on T
lymphocyte activation in patients with type 2 DM (17). There-
fore, the standard therapy of sitagliptin might not affect T
lymphocyte functions. Furthermore, the present study demon-
strated that DFS and GLP-1 acted on the intracellular signaling
cascade, although it was not clear that DFS and GLP-1 affected
macrophage phenotypic polarity shift from classic to alternative
macrophages. However, because DPP-4 inhibitors are relatively
new drugs, further in vivo and in vitro studies are needed for
complete evaluations of the long-term effects of DPP-4 inhibitors
on T lymphocyte and macrophage functions and vascular wall
cells.
Study limitations. The plasma levels of active GLP-1 were
measured in only a small number of patients. Medications
commonly used for the treatment of patients with chronic
diseases may affect plasma levels of active GLP-1. Thus, a
multicenter trial that includes a large population is war-
ranted to further examine the association between plasma
levels of active GLP-1 and the presence of CAD and the
antiatherogenic effects of DPP-4 inhibitors in humans.
Conclusions
The present study demonstrated that DFS, a DPP-4 inhib-
itor, significantly improved endothelial function and re-
duced atherosclerotic lesion formation in apoE-deficient
mice on an HFD, independent of lipid profile. The anti-
atherogenic effects of DPP-4 inhibitors on macrophages
and endothelial cells through the enhancement of GLP-1
activity could be beneficial to cardiovascular function.
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APPENDIX
For an expanded Methods section and supplemental
figures and tables, please see the online version of this article.
